Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) EBITDA (2022 - 2025)

Historic EBITDA for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$14.2 million.

  • BioXcel Therapeutics' EBITDA rose 696.4% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.7 million, marking a year-over-year increase of 3387.19%. This contributed to the annual value of -$67.2 million for FY2024, which is 6085.45% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported EBITDA of -$14.2 million as of Q3 2025, which was up 696.4% from -$15.9 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year EBITDA high stood at -$10.1 million for Q1 2025, and its period low was -$52.9 million during Q4 2022.
  • Its 4-year average for EBITDA is -$29.3 million, with a median of -$24.2 million in 2024.
  • In the last 5 years, BioXcel Therapeutics' EBITDA tumbled by 6263.66% in 2023 and then soared by 6833.55% in 2024.
  • BioXcel Therapeutics' EBITDA (Quarter) stood at -$52.9 million in 2022, then surged by 62.42% to -$19.9 million in 2023, then surged by 47.21% to -$10.5 million in 2024, then tumbled by 35.6% to -$14.2 million in 2025.
  • Its EBITDA was -$14.2 million in Q3 2025, compared to -$15.9 million in Q2 2025 and -$10.1 million in Q1 2025.